ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1444

HLA-DR3 Controls Autoantibody Response to Sm in NZM2328.DR3+.AE0 Transgenic Mice

Vaidehi R. Chowdhary1, Chao Dai2, Shu Man Fu2 and Chella S. David3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Medicine/CIIR/Rheumatology, University of Virginia Health System, Charlottesville, VA, 3Departement of Immunology, Mayo Clinic, Rochester, MN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Large genome wide scans have confirmed the strong association of HLA -DR3 with risk of developing SLE and antibody response to Sm which is specific to lupus. To understand the role of HLA-DR3 in pathogenesis of lupus and anti- Sm response, we generated NZM2328 mice transgenically expressing HLA-DR3 and devoid of endogenous mouse class II (AE0). Female NZM2328 spontaneously develop anti-dsDNA and severe glomerulonephritis whereas incidence of glomerulonephritis is less in male mice.

Methods: HLA DR3.AE0 transgenic mice were repeatedly backcrossed to NZM2328 mice for 6 generations. Mice were genotyped by PCR and Flow cytometry. Various cohorts of mice were followed monthly for proteinuria using Albustix and sera collected. Urinary protein greater than 300 mg/dL (3+ or more) was considered significant. Anti-Sm antibodies were determined by ELISA and immunoprecipitation.

Results:

The overall incidence of proteinuria in female NZM2328.DR3+.AE0 and NZM2328 mice at 12 months was 58% and 62% respectively (p=0.38) whereas male mice, as expected, had low incidence of proteinuria namely 11% in NZM2328 and 19% in NZM2328.DR3+.AE0. No proteinuria was seen in DR3+ .AE0 and AE0 mice. Both NZM2328 and NZM2328.DR3+.AE0 developed anti-dsDNA antibodies. NZM2328 males and females, AE0 and DR3+AE0 mice did not develop anti-Sm antibodies whereas both male and female NZM2328.DR3+.AE0 mice developed anti-Sm antibodies.  Preliminary results from immunoprecipitation in few samples also confirm presence of anti-Sm antibody in NZM2328.DR3+.AE0 mice. These mice develop glomerulonephritis and kidney scores are shown in Table 1.

Total number of spleen cells, CD4+, CD8+, B220+ and Mac1+ cells were enumerated in NZM2328, NZM2328.DR3+ AE0 mice and were not significantly different. Similarly the total numbers of thymocytes, CD4, CD8 double negative, double positive, single positives were also not different in both the groups. Certain CD4+, CD8+ T cell Vβ families were increased in NZM2328 and NZM2328. DR3+.AE0 mice compared to DR3+AE0 mice.  

Conclusion:

These results strongly support that that HLA-DR3, in an autoimmune prone background, plays an important role in generating an immune response to Sm and development of glomerulonephritis.


Disclosure:

V. R. Chowdhary,
None;

C. Dai,
None;

S. M. Fu,
None;

C. S. David,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-dr3-controls-autoantibody-response-to-sm-in-nzm2328-dr3-ae0-transgenic-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology